A wave of low-cost generic weight-loss drugs is poised to reshape the global fight against obesity following the expiry of a key patent for semaglutide in India on Friday. The development is expected to significantly expand access to treatments previously considered unaffordable for many, particularly in middle-income countries. Semaglutide, the…
